Physician profile
Christopher L Slack
NPI 1982613717
$3,075.76
in general payments reported to CMS, 2019-2025
29 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $260 · 2021: $320 · 2022: $501 · 2023: $270 · 2024: $507 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.07 |
| Education | $113.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $482.36 | 2020-2025 | Hyqvia, Glassia, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $420.26 | 2019-2025 | Dupixent |
| Fisher & Paykel Healthcare INC | $262.06 | 2019-2024 | Fisher & Paykel Healthcare |
| Optinose US, INC. | $229.82 | 2019-2025 | |
| Genzyme Corporation | $222.46 | 2019-2025 | |
| Smith+Nephew, INC. | $206.90 | 2019-2025 | Tula |
| Jazz Pharmaceuticals INC. | $190.37 | 2019-2021 | |
| Acclarent, INC | $114.41 | 2019 | |
| Glaxosmithkline, LLC. | $111.05 | 2022-2025 | Nucala |
| Stryker Corporation | $106.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $95.13 | 2020-2025 | Airsupra, Tezspire |
| Alk-Abello, INC | $82.74 | 2020-2021 | |
| Kaleo, INC. | $64.40 | 2020-2022 | |
| Amgen INC. | $54.00 | 2025 | |
| Octapharma USA, INC. | $53.24 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photonicare INC | $47.16 | 2025 | Otosight Middle Ear Scope |
| Merz North America, INC. | $43.75 | 2019 | |
| Lilly USA, LLC | $40.06 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $34.04 | 2019-2021 | |
| Galderma Laboratories, L.P. | $29.32 | 2020-2022 | |
| Tactile Systems Technology INC | $28.76 | 2024 | Flexitouch Plus, Entre Plus |
| Csl Behring | $24.26 | 2022 | |
| Insmed, INC. | $23.37 | 2025 | Arikayce |
| Neurent Medical Limited | $23.06 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Cochlear Americas | $19.01 | 2025 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Hologic Sales and Service, LLC | $17.95 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.21 | 2022 | |
| Aerin Medical INC. | $16.49 | 2020 | |
| Merck Sharp & Dohme LLC | $15.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Slack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.